Revenue has contracted sharply to $19.4M in 2026Q3 with gross margin ranging between 43.0% and 55.9%, yet operating margin of -102.0% indicates overhead reduction has not closed the profitability gap.
Standard BioTools Inc. (LAB) annual income statement — 20-year revenue, gross profit & net income history
| Metric | TTM | Dec'25 | Dec'24 | Dec'23 | Dec'22 | Dec'21 | Dec'20 | Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | Dec'14 | Dec'13 | Dec'12 | Dec'11 | Dec'10 | Dec'09 | Dec'08 | Dec'07 | Dec'06 |
|---|
| Sales/Revenue | 84.43M | 85.33M | 174.43M | 106.34M | 97.95M | 130.58M | 138.14M | 117.24M | 112.96M | 101.94M | 104.45M | 114.71M | 116.46M | 71.18M | 52.33M | 42.87M | 33.56M | 25.41M | 15.35M | 7.28M | 6.4M |
| Revenue Growth % | -22.01% | -51.08% | 64.03% | 8.57% | -24.99% | -5.47% | 17.83% | 3.79% | 10.82% | -2.4% | -8.95% | -1.5% | 63.6% | 36.02% | 22.09% | 27.73% | 32.06% | 65.58% | 110.96% | 13.71% | - |
| Cost of Goods Sold | 41.52M | 42.79M | 90.17M | 55.89M | 60.9M | 61.21M | 54.82M | 52.96M | 51.31M | 49.95M | 46.01M | 46.63M | 42.85M | 20.08M | 15.32M | 13.19M | 11.58M | 11.49M | 8.36M | 3.51M | 2.77M |
| COGS % of Revenue | - | 50.14% | 51.69% | 52.56% | 62.17% | 46.87% | 39.68% | 45.17% | 45.43% | 49.01% | 44.05% | 40.65% | 36.79% | 28.21% | 29.28% | 30.77% | 34.51% | 45.2% | 54.5% | 48.3% | 43.34% |
| Gross Profit | 42.91M | 42.54M | 84.26M | 50.45M | 37.05M | 69.37M | 83.33M | 64.28M | 61.65M | 51.98M | 58.44M | 68.08M | 73.61M | 51.1M | 37.01M | 29.67M | 21.98M | 13.93M | 6.98M | 3.76M | 3.63M |
| Gross Margin % | 50.82% | 49.86% | 48.31% | 47.44% | 37.83% | 53.13% | 60.32% | 54.83% | 54.57% | 50.99% | 55.95% | 59.35% | 63.21% | 71.79% | 70.72% | 69.23% | 65.49% | 54.8% | 45.5% | 51.7% | 56.66% |
| Gross Profit Growth % | - | -49.51% | 67.02% | 36.16% | -46.59% | -16.75% | 29.63% | 4.27% | 18.6% | -11.05% | -14.17% | -7.51% | 44.04% | 38.08% | 24.72% | 35.01% | 57.83% | 99.43% | 85.67% | 3.75% | - |
| Operating Expenses | 119.41M | 135.85M | 259.5M | 127.05M | 153.26M | 136.83M | 134.36M | 116.12M | 109.81M | 110.34M | 131.63M | 122.22M | 114.75M | 67.78M | 55.08M | 45.24M | 36.55M | 31.96M | 36.53M | 27.29M | 25.29M |
| OpEx % of Revenue | - | 159.2% | 148.77% | 119.48% | 156.47% | 104.79% | 97.26% | 99.04% | 97.21% | 108.25% | 126.02% | 106.55% | 98.53% | 95.23% | 105.25% | 105.54% | 108.92% | 125.78% | 238% | 375.08% | 395.25% |
| Selling, General & Admin | 76.22M | 109.86M | 156.61M | 87.54M | 102.28M | 98.89M | 97.9M | 84.48M | 79.78M | 79.52M | 93.21M | 82.96M | 71.32M | 48.05M | 38.48M | 31.3M | 23.55M | 19.65M | 22.51M | 12.9M | 9.7M |
| SG&A % of Revenue | - | 128.75% | 89.78% | 82.32% | 104.43% | 75.73% | 70.87% | 72.05% | 70.63% | 78% | 89.24% | 72.32% | 61.25% | 67.51% | 73.52% | 73.03% | 70.16% | 77.32% | 146.68% | 177.29% | 151.59% |
| Research & Development | 13.96M | 25.99M | 62.41M | 25.95M | 37.38M | 37.94M | 36.46M | 31.64M | 30.03M | 30.83M | 38.41M | 39.26M | 43.42M | 19.73M | 16.6M | 13.94M | 13.01M | 12.31M | 14.02M | 14.39M | 15.59M |
| R&D % of Revenue | - | 30.45% | 35.78% | 24.4% | 38.17% | 29.06% | 26.39% | 26.99% | 26.58% | 30.24% | 36.78% | 34.23% | 37.29% | 27.72% | 31.72% | 32.51% | 38.76% | 48.46% | 91.32% | 197.79% | 243.65% |
| Other Operating Expenses | 2M | 0 | 40.48M | 13.56M | 13.59M | 0 | 0 | 0 | 637K | 385K | -1.17M | -1.16M | -857K | 502K | -189K | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -76.5M | -93.31M | -175.24M | -76.6M | -116.2M | -67.46M | -51.04M | -51.84M | -48.16M | -58.36M | -73.19M | -50.16M | -51.84M | -17.95M | -18.07M | -18.57M | -14.57M | -18.04M | -29.54M | -23.53M | -21.66M |
| Operating Margin % | -90.6% | -109.34% | -100.46% | -72.03% | -118.64% | -51.66% | -36.94% | -44.21% | -42.64% | -57.25% | -70.07% | -43.72% | -44.51% | -25.22% | -34.53% | -43.31% | -43.42% | -70.98% | -192.5% | -323.38% | -338.59% |
| Operating Income Growth % | - | 46.75% | -128.77% | 34.08% | -72.26% | -32.18% | 1.55% | -7.63% | 17.47% | 20.26% | -45.93% | 3.24% | -188.78% | 0.67% | 2.67% | -27.4% | 19.2% | 38.95% | -25.58% | -8.6% | - |
| EBITDA | -71.32M | -82.33M | -158.38M | -61.42M | -101.18M | -51.89M | -35.11M | -36.03M | -31.59M | -39.75M | -55.25M | -34.04M | -47.77M | -15.4M | -16.59M | -17.5M | -13.07M | -16.1M | -27.58M | -21.39M | -20.2M |
| EBITDA Margin % | -84.47% | -96.48% | -90.79% | -57.76% | -103.3% | -39.74% | -25.42% | -30.73% | -27.97% | -39% | -52.9% | -29.67% | -41.02% | -21.63% | -31.7% | -40.84% | -38.94% | -63.34% | -179.68% | -293.99% | -315.79% |
| EBITDA Growth % | 22.94% | 48.02% | -157.86% | 39.3% | -94.99% | -47.78% | 2.56% | -14.06% | 20.53% | 28.06% | -62.31% | 28.75% | -210.25% | 7.17% | 5.23% | -33.94% | 18.81% | 41.63% | -28.93% | -5.86% | - |
| D&A (Non-Cash Add-back) | 5.17M | 10.98M | 16.86M | 15.18M | 15.03M | 15.57M | 15.92M | 15.8M | 16.57M | 18.61M | 17.94M | 16.11M | 4.06M | 2.55M | 1.48M | 1.06M | 1.5M | 1.94M | 1.97M | 2.14M | 1.46M |
| EBIT | -80.93M | -96.68M | -135M | -69.64M | -188.6M | -59.84M | -50.53M | -62.43M | -47.53M | -57.98M | -74.36M | -48.98M | -52.36M | -16.38M | -18.26M | -19.2M | -14.66M | -16.3M | -27.61M | -22.56M | -21.29M |
| Net Interest Income | 10.05M | 9.15M | 16.88M | 1M | -2.1M | -3.82M | -3.57M | -4.28M | -13.89M | -5.82M | -5.82M | -5.81M | -5.34M | -14K | -628K | -3.1M | -2.16M | -2.84M | -1.26M | -1.65M | -1.7M |
| Interest Income | 10.05M | 9.18M | 20.2M | 5.57M | 2.23M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 37K | 766K | 1.14M | 565K |
| Interest Expense | 5K | 26K | 3.32M | 4.57M | 4.33M | 3.82M | 3.57M | 4.28M | 13.89M | 5.82M | 5.82M | 5.81M | 5.34M | 14K | 628K | 3.1M | 2.16M | 2.88M | 2.03M | 2.79M | 2.26M |
| Other Income/Expense | 3.46M | -3.4M | 36.92M | 2.4M | -76.72M | 3.8M | -3.06M | -14.87M | -13.26M | -5.44M | -6.99M | -4.63M | -5.87M | 2.26M | -817K | -3.74M | -2.25M | -1.14M | -103K | -1.82M | -1.89M |
| Pretax Income | -73.03M | -96.7M | -138.31M | -74.2M | -192.93M | -63.66M | -54.1M | -66.7M | -61.42M | -63.8M | -80.18M | -54.79M | -57.7M | -15.69M | -18.89M | -22.3M | -16.82M | -19.18M | -29.65M | -25.35M | -23.55M |
| Pretax Margin % | -86.5% | -113.33% | -79.29% | -69.78% | -196.97% | -48.75% | -39.16% | -56.89% | -54.37% | -62.59% | -76.76% | -47.76% | -49.55% | -22.03% | -36.09% | -52.03% | -50.12% | -75.47% | -193.17% | -348.4% | -368.13% |
| Income Tax | -35.8M | -37.88M | 573K | 452K | -2.83M | -4.42M | -1.08M | -1.92M | -2.41M | -3.26M | -4.19M | -1.48M | -4.88M | 137K | 136K | 166K | 83K | -50K | -147K | 105K | 194K |
| Effective Tax Rate % | 49.03% | 39.17% | -0.41% | -0.61% | 1.47% | 6.95% | 2% | 2.87% | 3.92% | 5.12% | 5.23% | 2.69% | 8.45% | -0.87% | -0.72% | -0.74% | -0.49% | 0.26% | 0.5% | -0.41% | -0.82% |
| Net Income | -39.21M | -74.9M | -138.88M | -74.66M | -190.1M | -59.24M | -53.02M | -64.79M | -59.01M | -60.53M | -75.98M | -53.31M | -52.83M | -15.82M | -19.02M | -22.47M | -16.9M | -19.13M | -29.5M | -25.45M | -23.55M |
| Net Margin % | -46.44% | -87.77% | -79.62% | -70.2% | -194.08% | -45.36% | -38.38% | -55.26% | -52.24% | -59.38% | -72.75% | -46.48% | -45.36% | -22.23% | -36.35% | -52.42% | -50.36% | -75.27% | -192.21% | -349.84% | -368.13% |
| Net Income Growth % | 69.42% | 46.07% | -86.03% | 60.73% | -220.91% | -11.73% | 18.17% | -9.79% | 2.51% | 20.33% | -42.52% | -0.92% | -233.9% | 16.83% | 15.34% | -32.94% | 11.64% | 35.16% | -15.91% | -8.06% | - |
| Net Income (Continuing) | -37.23M | -58.83M | -138.88M | -74.66M | -190.1M | -59.24M | -53.02M | -64.79M | -59.01M | -60.53M | -75.98M | -53.31M | -52.83M | -16.53M | -19.02M | -22.47M | -16.9M | -19.13M | -29.5M | -25.45M | -23.55M |
| Discontinued Operations | 0 | -16.07M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.10 | -0.20 | -0.52 | -0.94 | -2.43 | -0.78 | -0.74 | -0.97 | -1.49 | -1.84 | -2.62 | -1.86 | -1.90 | -0.62 | -0.86 | -1.26 | -0.89 | -11.02 | -17.85 | -13.47 | -12.46 |
| EPS Growth % | 67.73% | 61.54% | 44.68% | 61.32% | -211.54% | -5.41% | 23.71% | 34.9% | 19.02% | 29.77% | -40.86% | 2.11% | -206.45% | 27.91% | 31.75% | -41.57% | 91.92% | 38.26% | -32.52% | -8.11% | - |
| EPS (Basic) | - | -0.20 | -0.52 | -0.94 | -2.43 | -0.78 | -0.74 | -0.97 | -1.49 | -1.84 | -2.62 | -1.86 | -1.90 | -0.62 | -0.86 | -1.26 | -0.89 | -11.02 | -17.85 | -13.47 | -12.46 |
| Diluted Shares Outstanding | 393.56M | 381.62M | 352.67M | 79.16M | 78.31M | 75.79M | 72.04M | 66.78M | 39.65M | 32.98M | 29.01M | 28.71M | 27.77M | 25.48M | 22.14M | 17.85M | 18.98M | 1.74M | 1.65M | 1.89M | 1.89M |
| Basic Shares Outstanding | 393.56M | 381.62M | 352.67M | 79.16M | 78.31M | 75.79M | 72.04M | 66.78M | 39.65M | 32.98M | 29.01M | 28.71M | 27.77M | 25.48M | 22.14M | 17.85M | 18.98M | 1.74M | 1.65M | 1.89M | 1.89M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quick answers to the most common questions about buying LAB stock.
For fiscal year 2025, Standard BioTools Inc. (LAB) reported total revenue of $85.3M. This represents a 1233.7% increase compared to $6.4M in 2006.
Standard BioTools Inc. (LAB) reported a net loss of $74.9M for the fiscal year ending 2025.
Standard BioTools Inc. (LAB) reported an operating income of $-93.3M, resulting in an operating profit margin of -109.3%. This margin reflects the operational efficiency of the business before interest and taxes.
Standard BioTools Inc. (LAB) generated $42.5M in gross profit for the year, representing a gross profit margin of 49.9%. This demonstrates the company's core pricing power and production efficiency.
Key Metrics
Top Statement Risk
Persistent operating losses
Metrics are mathematically derived from official filings.
Revenue Stabilizing After Steep Decline
Based on reported quarterly figures, LAB revenue fell from $46.7M in 2024Q4 to $19.4M in 2026Q3, with the most recent quarters showing near-flat sequential movement around $19M to $21M, suggesting the base may be stabilizing at a far lower level.
The 2024Q4 revenue peak appears to have been elevated by items that did not recur, as quarterly revenue stepped down sharply in 2025 and has held within a narrow band since. Year-over-year comparisons are flattered in some quarters and punished in others, so the sequence rather than any single growth rate better reflects the underlying trend. Investors should monitor whether revenue can grow off this reset base, since the reported figures alone do not establish a durable recovery.
Gross Margin Volatility Without Clear Trend
As reported in the income statements, LAB gross margin ranged from 43.0% to 55.9% across the ten quarters, with the latest quarter at 55.9% compared with 46.9% a year earlier, indicating meaningful quarter-to-quarter variability in product mix or cost absorption.
Gross margin has swung widely rather than following a steady expansion path, which suggests sensitivity to revenue scale and cost absorption at a small revenue base. The 2026Q3 margin sits at the top of the observed range, but one quarter is insufficient to establish a structural improvement. Relative to peers such as PACB at 31.7% and NTRA at 64.8%, LAB's gross margin is mid-range, which implies its pricing power is neither clearly superior nor weak.
Operating Losses Persist Despite Cost Cuts
Based on reported figures, LAB operating loss was -$19.8M in 2026Q3 against -$32.8M in 2024Q4, while SG&A fell from $37.6M to $16.8M, indicating overhead reduction has been substantial yet has not closed the gap to profitability.
Operating expenses have been cut materially, yet operating margin remained deeply negative at -102.0% in the latest quarter, meaning revenue scale has not yet caught up with the remaining cost base. The reduction in SG&A is significant, but the operating loss in 2026Q3 is still larger in absolute terms than gross profit, indicating operating leverage is not yet working in the company's favor. Further analysis is warranted to determine how much of the remaining cost base is fixed versus discretionary.
Net Income Swings Driven by Non-Operating Items
As reported, LAB net income moved from -$45.2M in 2026Q1 to +$13.5M in 2026Q3 while operating income remained negative in both periods, suggesting the bottom-line swings are driven by items outside core operations.
The divergence between operating loss and positive net income in 2026Q3, and the reverse pattern in other quarters, indicates that non-operating items such as gains, losses, or tax effects are materially influencing reported earnings. Net margin figures like 69.6% and -177.4% therefore reflect noise more than operating performance. Stock-based compensation of $3.7M to $12.9M per quarter is also a non-trivial share of the cost base, which warrants further investigation into its effect on reported earnings quality.
Positive Quarter May Not Signal Recovery
The strongest bear case rests on the fact that LAB reported positive net income of $13.5M in 2026Q3 while operating margin remained at -102.0%, a pattern that short-sellers would likely flag as non-recurring rather than evidence of sustainable profitability.
A single quarter of positive net income, set against sustained negative operating income and stagnant revenue around $19M to $21M, may be interpreted as a one-off rather than a turn in the business. Revenue has not demonstrated consistent growth since the 2024 peak, and the operating loss remains the dominant feature of the income statement. Investors should monitor whether operating losses narrow across several consecutive quarters before attributing the latest result to improving fundamentals.